Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of Tuesday, October 6, 2026.
RETURN ON ASSETS (ROA)
N/A
Scribe Therapeutics Inc.
Market Cap
$264.25M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
Return on Assets (ROA)
-45.18%
TTM Avg
-124.83%
3Y Avg
-176.38%
5Y Avg
-195.56%
Market Cap
$265.78M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$266.59M
Return on Assets (ROA)
-5.36%
TTM Avg
-34.75%
3Y Avg
-39.14%
5Y Avg
-23.69%
Market Cap
$266.92M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$261.43M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$261.27M
Return on Assets (ROA)
-35.62%
TTM Avg
-26.42%
3Y Avg
-45.47%
5Y Avg
-51.35%
Market Cap
$259.56M
Return on Assets (ROA)
-13.63%
TTM Avg
-10.56%
3Y Avg
-3.47%
5Y Avg
-3.69%
Market Cap
$259.49M
Return on Assets (ROA)
-32.87%
TTM Avg
-28.32%
3Y Avg
-25.80%
5Y Avg
-21.10%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $264.25M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -45.18% | -124.83% | -176.38% | -195.56% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -134.38% | -47.50% | -42.91% | -40.55% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | -5.36% | -34.75% | -39.14% | -23.69% |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -48.44% | -42.51% | -39.18% | -34.60% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | -37.07% | -27.27% | -64.53% | -52.03% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | -35.62% | -26.42% | -45.47% | -51.35% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | -13.63% | -10.56% | -3.47% | -3.69% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | -32.87% | -28.32% | -25.80% | -21.10% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | -35.96% | -58.88% | -82.10% | -113.46% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
